Global LV-Based Cell and Gene Therapy Products Market Growth (Status and Outlook) 2024-2030

Global LV-Based Cell and Gene Therapy Products Market Growth (Status and Outlook) 2024-2030

LV-based cell and gene therapy products refer to therapeutic products that utilize lentiviral vectors (LV) as a delivery system for introducing genetic material into target cells. Lentiviral vectors are commonly used in gene therapy to transfer genes into cells for the treatment of genetic disorders, cancer, and other diseases.

The global LV-Based Cell and Gene Therapy Products market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “LV-Based Cell and Gene Therapy Products Industry Forecast” looks at past sales and reviews total world LV-Based Cell and Gene Therapy Products sales in 2022, providing a comprehensive analysis by region and market sector of projected LV-Based Cell and Gene Therapy Products sales for 2023 through 2029. With LV-Based Cell and Gene Therapy Products sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world LV-Based Cell and Gene Therapy Products industry.

This Insight Report provides a comprehensive analysis of the global LV-Based Cell and Gene Therapy Products landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on LV-Based Cell and Gene Therapy Products portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global LV-Based Cell and Gene Therapy Products market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for LV-Based Cell and Gene Therapy Products and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global LV-Based Cell and Gene Therapy Products.

United States market for LV-Based Cell and Gene Therapy Products is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for LV-Based Cell and Gene Therapy Products is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for LV-Based Cell and Gene Therapy Products is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key LV-Based Cell and Gene Therapy Products players cover Novartis, Bluebird Bio, Thermo Fisher Scientific, Intas, BMS, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of LV-Based Cell and Gene Therapy Products market by product type, application, key players and key regions and countries.

Segmentation by Type:
CAR-T Therapy
Autologous CD34+ Cell Gene Therapy

Segmentation by Application:
Hospital
Diagnostic and Testing Laboratories
Academic and Research Organizations
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
CAR-T Therapy
Autologous CD34+ Cell Gene Therapy

Segmentation by Application:
Hospital
Diagnostic and Testing Laboratories
Academic and Research Organizations
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Bluebird Bio
Thermo Fisher Scientific
Intas
BMS
Orchard Therapeutics

Please note: The report will take approximately 2 business days to prepare and deliver.